CoChat

RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

Min, Ahrum, Im, Seock-Ah, Yoon, Young-Kwang, Song, Sang-Hyun, Nam, Hyun-Jin, Hur, Hyung-Seok, Kim, Hwang-Phill, Lee, Kyung-Hun, Han, Sae-Won, Oh, Do-Youn, Kim, Tae-You, O'Connor, Mark J., Kim, Woo-Ho, Bang, Yung-Jue · 2013 · Molecular Cancer Therapeutics
Cited by 141

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

A PARP inhibitor is a rationally designed targeted therapy for cancers with impaired DNA repair abilities. RAD51C is a paralog of RAD51 that has an important role in the DNA damage response. We found that cell lines sensitive to a novel oral PARP inhibitor, olaparib, had low levels of RAD51C expression using microarray analysis, and we therefore hypothesized that low expression of RAD51C may hamper the DNA repair process, resulting in increased sensitivity to olaparib. Compared with the cells with normal RAD51C expression levels, RAD51C-deficient cancer cells were more sensitive to olaparib, and a higher proportion underwent cell death by inducing G2–M cell-cycle arrest and apoptosis. The restoration of RAD51C in a sensitive cell line caused attenuation of olaparib sensitivity. In contrast, silencing of RAD51C in a resistant cell line enhanced the sensitivity to olaparib, and the number of RAD51 foci decreased with ablated RAD51C expression. We also found the expression of RAD51C was downregulated in cancer cells due to epigenetic changes and RAD51C expression was low in some gastric cancer tissues. Furthermore, olaparib significantly suppressed RAD51C-deficient tumor growth in a xenograft model. In summary, RAD51C-deficient cancer cells are highly sensitive to olaparib and offer preclinical proof-of-principle that RAD51C deficiency may be considered a biomarker for predicting the antitumor effects of olaparib. Mol Cancer Ther; 12(6); 865–77. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-12-0950

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 141

Metadata

Authors
Min, A., Im, S.-A., Yoon, Y.-K., Song, S.-H., Nam, H.-J., Hur, H.-S., Kim, H.-P., Lee, K.-H., Han, S.-W., Oh, D.-Y., Kim, T.-Y., O'Connor, M. J., Kim, W.-H., & Bang, Y.-J.
Venue
Molecular Cancer Therapeutics
Published
2013-06-01
Volume
12
Issue
6
Pages
865-877
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2151876400
Cited by
141
References
5
FWCI
5.69
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib. https://app.cochat.ai/papers/10.1158/1535-7163.mct-12-0950
The paper
Min, A., Im, S.-A., Yoon, Y.-K., Song, S.-H., Nam, H.-J., Hur, H.-S., Kim, H.-P., Lee, K.-H., Han, S.-W., Oh, D.-Y., Kim, T.-Y., O'Connor, M. J., Kim, W.-H., & Bang, Y.-J. (2013). RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-12-0950

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.